BOULDER, Colo., IRVINE, Calif. and LIEGE, Belgium, June 26, 2014 /PRNewswire/ -- BiOptix, in conjunction with Altermune Technologies announced today the presentation of a poster for "Quantitative SPR Screening of Aptamer-Protein Interactions for Pre-Clinical Development" at the Drug Analysis 2014 meeting in Liege, Belgium. The meeting combines the 10(th) International Symposium of Drug Analysis and the 25(th) Annual International Symposium on Pharmaceutical and Biomedical Analysis and is considered to be one of the leading European events on the topic of drug analysis, discovery and research. Additional information about the symposia can be found at:www.druganalysis.org
The data presented uses the BiOptix 404pi SPR instrument in conjunction with Aptamer technology developed by Altermune. 'Using the BiOptix 404pi was fast, efficient and reliable - the machine generates excellent kinetic results and truly highlights Altermune's Alphamer(TM) technology," noted Dr. Paul Hatala, Head of Discovery Research for Altermune. "The machine can be utilized during both candidate screening and through lead optimization pipelines," noted Dr. Bradley Hall, Lead Scientist of Product Development for Altermune Technologies. "Altermune Technologies is at the forefront of aptamer research, and has been an ideal research partner for BiOptix," commented Ken Wilczek, Vice President, Sales & Marketing for BiOptix. "We look forward to our continued collaboration with Altermune Technologies and to the advancement of science through aptamer research using the BiOptix 404pi."
BiOptix Diagnostics is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures, Remeditex and Rusnano. BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR - Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction--with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at: www.bioptix.com
Altermune Technologies is a privately held research organization based in Irvine, California with a leading investment from Loxbridge Research. With a focus on Alphamer(TM) technology, Altermune Technologies is focused on the development of novel therapeutics to combat resistant pathogens such as MRSA, C. difficile, pseudomonas, and pandemic influenza. Altermune Technologies is pioneering the use of "programmable immunity" in which 'linker' molecules redirect naturally occurring antibodies to selected pathogens. The linker molecules has two distinct ends: one binds a consistent cell-surface target on the pathogen using an aptamer (a single stranded oligonucleotide), whereas the other end presents specific epitopes that attract the circulating antibodies. Additional information about Altermune Technologies can be found at: www.altermune.com